Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel for Primary Prevention in Subclinical Coronary Atherosclerosis
NCT05845489Phase 4Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in coronary artery disease (CAD) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Major adverse cardiovascular and cerebrovascular events at 2 years. Started Mar 2023; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05845489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845489.